SCI: A Bayesian adaptive phase I/II dose-finding design accounting for semi-competing risks outcomes for immunotherapy trials.
Y, Zhang⋅Zhang, Yifei⋅B, Guo⋅Guo, Beibei⋅S, Cao⋅Cao, Sha⋅Zhang, Chi⋅C, Zhang⋅Y, Zang and Zang, Yong
Pharmaceutical statistics, March 24, 2022. | Journal Article